Form 4: Sangamo Therapeutics CFO Reports Stock Transactions for Tax Withholding

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units (RSUs).

Summary

• On May 24 and May 25, 2024, Prathyusha Duraibabu, the SVP and CFO of Sangamo Therapeutics, disposed of shares of common stock to cover tax withholding obligations related to the vesting of her RSU grants.
• A total of 1,787 shares were disposed of on May 24, 2024, and 1,371 shares were disposed of on May 25, 2024, both at a price of $0.60 per share.
• These transactions were not discretionary trades but were required for tax withholding purposes under the company's Amended and Restated 2018 Equity Incentive Plan.
• Following these transactions, Duraibabu beneficially owns 831,420 shares of Sangamo Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock transactions for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's performance or outlook.

Future Outlook

The CFO's remaining RSU grants will continue to vest in quarterly installments through February 2026, subject to continuous service.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to tax withholding and do not represent a change in the CFO's overall confidence in the company.

Key Dates